tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

KURA Stock Latest News

Kura Oncology reports inducement grants under Nasdaq listing rule
The FlyKura Oncology reports inducement grants under Nasdaq listing rule
21d ago
KURA
Kura Oncology Partners with Kyowa Kirin for Ziftomenib
PremiumCompany Announcements
Kura Oncology Partners with Kyowa Kirin for Ziftomenib
23d ago
8K
KURA
Promising Developments in Kura Oncology’s AML Treatment Drive Buy Rating
PremiumRatings
Promising Developments in Kura Oncology’s AML Treatment Drive Buy Rating
1M ago
KURA
Optimistic Outlook on Kura Oncology: Promising Developments in AML Treatment with Ziftomenib
PremiumRatings
Optimistic Outlook on Kura Oncology: Promising Developments in AML Treatment with Ziftomenib
1M ago
KURA
Kura Oncology Announces Positive Phase 1a/1b Trial Results
PremiumCompany Announcements
Kura Oncology Announces Positive Phase 1a/1b Trial Results
1M ago
8K
KURA
Cautious Hold on Kura Oncology Amid Promising Efficacy and Safety Concerns of Ziftomenib
PremiumRatingsCautious Hold on Kura Oncology Amid Promising Efficacy and Safety Concerns of Ziftomenib
1M ago
KURA
Promising Clinical Trial Results and Future Prospects Justify Buy Rating for Kura Oncology
Premium
Ratings
Promising Clinical Trial Results and Future Prospects Justify Buy Rating for Kura Oncology
1M ago
KURA
Kura Oncology, Kyowa Kirin provide clinical data from KOMET-007
Premium
The Fly
Kura Oncology, Kyowa Kirin provide clinical data from KOMET-007
1M ago
KURA
Kura Oncology Stockholders Approve Equity Plan Amendment
PremiumCompany Announcements
Kura Oncology Stockholders Approve Equity Plan Amendment
2M ago
8K
KURA
Kura Oncology reports inducement grants under Nasdaq listing rule
PremiumThe Fly
Kura Oncology reports inducement grants under Nasdaq listing rule
2M ago
KURA
Kura Oncology’s Promising Prospects: Buy Rating Affirmed on Strong KOMET-001 Data and FDA Priority Review
PremiumRatings
Kura Oncology’s Promising Prospects: Buy Rating Affirmed on Strong KOMET-001 Data and FDA Priority Review
2M ago
KURA
Kura Oncology data overhangs receding, says BofA
PremiumThe Fly
Kura Oncology data overhangs receding, says BofA
2M ago
KURA
Kura Oncology’s Ziftomenib: Promising Potential in R/R AML Market with Favorable FDA Review and Strategic Growth
PremiumRatingsKura Oncology’s Ziftomenib: Promising Potential in R/R AML Market with Favorable FDA Review and Strategic Growth
2M ago
KURA
Kura Oncology’s FDA Priority Review for Ziftomenib
Premium
Company Announcements
Kura Oncology’s FDA Priority Review for Ziftomenib
2M ago
8K
KURA
Kura Oncology says ‘positive’ results from KOMET-001 Phase 2 trial of ziftomenib
Premium
The Fly
Kura Oncology says ‘positive’ results from KOMET-001 Phase 2 trial of ziftomenib
2M ago
KURA
Kura Oncology’s Ziftomenib Gains FDA Priority Review, Promising Commercial Success in AML Treatment
PremiumRatings
Kura Oncology’s Ziftomenib Gains FDA Priority Review, Promising Commercial Success in AML Treatment
2M ago
KURA
Kura Oncology, Kyowa Kirin announces FDA accepted NDA for ziftomenib
PremiumThe Fly
Kura Oncology, Kyowa Kirin announces FDA accepted NDA for ziftomenib
2M ago
KURA
Promising Trial Data and Strategic Focus Drive Buy Rating for Kura Oncology
PremiumRatings
Promising Trial Data and Strategic Focus Drive Buy Rating for Kura Oncology
2M ago
KURA
Positive Outlook for Kura Oncology: Buy Rating Supported by Promising Clinical Results and Strategic Advancements
PremiumRatings
Positive Outlook for Kura Oncology: Buy Rating Supported by Promising Clinical Results and Strategic Advancements
2M ago
KURA
Kura Oncology price target lowered to $30 from $32 at Mizuho
PremiumThe FlyKura Oncology price target lowered to $30 from $32 at Mizuho
2M ago
KURA
Kura Oncology: Promising Clinical Trials and Stable Financials Justify Buy Rating
Premium
Ratings
Kura Oncology: Promising Clinical Trials and Stable Financials Justify Buy Rating
2M ago
KURA
Kura, Kyowa say ziftomenib abstract accepted for EHA Congress
Premium
The Fly
Kura, Kyowa say ziftomenib abstract accepted for EHA Congress
2M ago
KURA

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >